中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2018

Influence of time schedule of radiofrequency ablation on the safety and prognosis of patients with colorectal cancer liver metastasis receiving XELOX regimen: A single-center clinical study

DOI: 10.3969/j.issn.1001-5256.2018.12.019
Research funding:

 

  • Published Date: 2018-12-20
  • Objective To investigate the influence of time schedule of radiofrequency ablation (RFA) on the safety and prognosis of patients with colorectal cancer liver metastasis treated with RFA combined with XELOX regimen. Methods A retrospective analysis was performed for the clinical data of 48 patients with colorectal cancer liver metastasis who received RFA combined with XELOX regimen in Beijing Ditan Hospital from January 2011 to August 2017, and according to the time schedule of RFA, these patients were divided into group A (25 patients treated with RFA and sequential systemic chemotherapy ± targeted therapy) and group B (23 patients treated with chemotherapy ±targeted therapy and then RFA) . The patients with a stable disease or partial remission continued to take Xeloda orally until disease progression or intolerable side effects. The primary endpoint was objective response rate (ORR) of tumor, and the secondary endpoints included time to progression (TTP) , overall survival (OS) , and safety. Results There was no significant difference in ORR between group A and group B [68. 0% (8 patients with complete response and 9 with partial response) vs 43. 5% (2 patients with complete response and 9 with partial response) , χ2= 2. 927, P = 0. 087]. There were no significant differences between group A and group B in median TTP (9. 0 months vs 8. 0 months, χ2= 2. 660, P > 0. 05) and median OS (33 months vs 30 months, χ2= 0. 562, P > 0. 05) . For the patients with liver metastasis alone, there was a significant difference in median TTP between group A and group B (15. 0 months vs 8. 0 months, χ2= 4. 331, P = 0. 037) . Both groups had similar incidence and degree of common adverse events (AEs) (all P > 0. 05) . Most treatment-related AEs were mild or moderate; the most common mild AE (grade I/II) was leucopenia (93. 8%) , followed by nausea (91. 7%) and abdominal pain (81. 3%) . There were no fatal AEs, and the most common grade III/IV treatment-related AE was hematological toxicity observed in14 patients (29. 2%) . All AEs were resolved without sequelae. Conclusion RFA combined with XELOX-Xeloda maintenance chemotherapy is well tolerated and has a good clinical effect in patients with colorectal cancer liver metastasis. For patients with liver metastasis alone, RFA followed by chemotherapy can improve ORR of tumor.

     

  • [1] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66 (1) :7-30.
    [2] KANAS GP, TAYLOR A, PRIMROSE JN, et al. Survival after liver resection in metastatic colorectal cancer:Review and meta-analysis of prognostic factors[J]. Clin Epidemiol, 2012, 4:283-301.
    [3] van CUTSEM E, CERVANTES A, ADAM R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27 (8) :1386-1422.
    [4] BAI H, HUANGZ X, JING L, et al. The effect of radiofrequency ablation vs. liver resection on survival outcome of colorectal liver metastases (CRLM) :A meta-analysis[J]. Hepatogastroenterology, 2015, 62 (138) :373-377.
    [5] LIANG RF, ZHENG LL. The efficacy and safety of panitumumabin the treatment of patients with metastatic colorectal cancer:A meta-analysis from five randomized controlled trials[J]. Drug Des Devel Ther, 2015, 9:4471-4478.
    [6] YAMAZAKI K, NAGASE M, TAMAGAWA H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus m FOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) [J]. Ann Oncol, 2016, 27 (8) :1539-1546.
    [7] van CUTSEM E, LENZ HJ, KOHNE CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer[J]. J Clin Oncol, 2015, 33 (7) :692-700.
    [8] PETRELLI F, BARNI S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases:A meta-analysis[J]. Int J Colorectal Dis, 2012, 27 (8) :997-1004.
    [9] RUERS T, PUNT C, van COEVORDEN F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases:A randomized EORTC Intergroup phase II study (EORTC 40004) [J]. Ann Oncol, 2012, 23 (10) :2619-2626.
    [10] LI S, HE N, LI W, et al. Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer[J]. Chin J Cancer, 2014, 33 (6) :295-305.
    [11] BOAME N, GRESHAM G, JONKER D, et al. Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases:A retrospective review of The Ottawa Hospital Cancer Centreover 7years[J]. Curr Oncol, 2014, 21 (4) :e557-e563.
    [12] LUO HY, LI YH, WANG W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in firstline treatment of metastatic colorectal cancer:Randomized clinical trial of efficacy and safety[J]. Ann Oncol, 2016, 27 (6) :1074-1081.
    [13] BENDELL JC, ZAKARI A, PEYTON JD, et al. A phase II study of FOLFOXIRI plus panitumumab followed by evaluation for resection in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only[J]. Oncologist, 2016, 21 (3) :279-280.
    [14] LEONE F, ARTALE S, MARINO D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The Meta Pan study[J]. Cancer, 2013, 119 (19) :3429-3435.
    [15] TAKAHASHI T, SHIBATA Y, TOJIMA Y, et al. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan:ROOF study[J]. Int J Clin Oncol, 2013, 18 (2) :335-342.
    [16] FATOUROU EM, KOSKINAS JS. Adaptive immunity in hepatocellular carcinoma:Prognostic and therapeutic implications[J]. Expert Rev Anticancer Ther, 2009, 9 (10) :1499-1510.
    [17] ALESSANDRO Z, MASSIMO P, AMALIA P, et al. Radiofrequency thermal ablation hepatocellular carcinoma liver nodules responses[J].Cancer Res, 2006, 66 (23) :1139-1146.
    [18] ZERBINI A, PILLI M, FAGNONI F, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation[J]. J Immunother, 2008, 31 (3) :271-282.
    [19] ZERBINI A, PILLI M, LACCABUE D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response[J]. Gastroenterology, 2010, 138 (5) :1931-1942.
    [20] HOF J, WERTENBROEK MW, PEETERS PM, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases[J]. Br J Surg, 2016, 103 (8) :1055-1062.
    [21] HUANG CJ, TENG HW, CHIEN CC, et al. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer[J]. PLo S One, 2014, 8 (6) :e65117.
    [22] ASGHAR U, HAWKES E, CUNNINGHAM D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2010, 9 (5) :274-281.
    [23] CLANCY C, BURKE JP, KALADY MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer:A systematic review and meta-analysis[J]. Colorectal Dis, 2013, 15 (12) :e711-e718.
    [24] ACCIUFFI S, MEYER F, BAUSCHKE A, et al. Analysis of prognostic factors after resection of solitary liver metastasis in colorectal cancer:A22-year bicentre study[J]. J Cancer Res Clin Oncol, 2018, 144 (3) :593-599.
    [25] DING XY, CHEN JL, SUN W, et al. Safety and efficacy of lowdose IL-2 plus transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for the treatment of large primary liver cancer:A single-center experience[J]. Clin Med J, 2014, 12 (3) :22-28. (in Chinese) .丁晓燕, 陈京龙, 孙巍, 等.低剂量白介素-2联合肝动脉化疗栓塞术序贯CT引导下射频消融术在≥5 cm的原发性肝癌的疗效和安全性[J].临床药物治疗杂志, 2014, 12 (3) :22-28.
    [26] FRANCICA G, PETROLATI A, DI-STASIO E, et al. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location[J]. AJR Am J Roentgenol, 2012, 199 (6) :1393-1401.
  • Relative Articles

    [1]Xiaoqing WANG, Jie LONG, Fei WANG, Zhexiong LIAN. Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer[J]. Journal of Clinical Hepatology, 2024, 40(6): 1183-1190. doi: 10.12449/JCH240618
    [2]Rui ZHANG, Jinhong CHEN. Treatment strategy of non-radical surgical resection for colorectal cancer liver metastases[J]. Journal of Clinical Hepatology, 2024, 40(7): 1295-1300. doi: 10.12449/JCH240702
    [3]Chinese College of Surgeons, Chinese Medical Doctor Association, Chinese Society Gastrointestinal Surgery, Chinese Society of Surgery, Chinese Medical Association, Chinese Society of Colorectal Surgery, Chinese Society of Surgery, Chinese Medical Association, Section of Colorectal Oncology, Chinese Society of Oncology, Chinese Medical Association, Colorectal Cancer Professional Committee, Chinese Anti-Cancer Association, Colorectal Cancer Professional Committee, Chinese Medical Doctor Association, Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology, Chinese College of Colorectal Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association, Metastasis Research Committee, Anorectal Branch of Chinese Medical Doctor Association, Colorectal Liver Metastases Professional Committee, China International Exchange and Promotive Association for Medical and Health Care. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (2020 edition)[J]. Journal of Clinical Hepatology, 2021, 37(3): 543-553. doi: 10.3969/j.issn.1001-5256.2021.03.009
    [4]Xuemin LI, Hao WANG, Junjie WANG. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2021, 37(3): 522-526. doi: 10.3969/j.issn.1001-5256.2021.03.006
    [5]Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
    [6]Gao BenJian, Luo Jia, Liu Ying, Yang XiaoLi, Su Song, Li Bo. Efficacy and safety of laparoscopic versus open liver resection in treatment of colorectal cancer liver metastasis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(3): 573-579. doi: 10.3969/j.issn.1001-5256.2020.03.021
    [7]Li Jiang, Hou Yu, Cai XiaoBei, Xu ChengLei, Yi GenFa. Clinical effect of local treatment based on limited segmental resection in improving the prognosis of liver oligometastasis after surgery for colorectal cancer[J]. Journal of Clinical Hepatology, 2020, 36(8): 1763-1767. doi: 10.3969/j.issn.1001-5256.2020.08.017
    [8]Liao Yang, Li ShengWei. Current status of associating liver partition and portal vein ligation for staged hepatectomy in treatment of liver metastasis of colorectal cancer[J]. Journal of Clinical Hepatology, 2019, 35(12): 2805-2808. doi: 10.3969/j.issn.1001-5256.2019.12.035
    [9]Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046
    [10]Min YongFeng, Zhang Bo. Microwave ablation combined with 125I particle implantation in treatment of hepatic metastasis with diaphragm perforation: A case report[J]. Journal of Clinical Hepatology, 2018, 34(8): 1758-1759. doi: 10.3969/j.issn.1001-5256.2018.08.034
    [11]Li Hao, Duan XuHua, Han XinWei, Ren JianZhuang, Li FengYao, Kuang DongLin, Li FangZheng. Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors[J]. Journal of Clinical Hepatology, 2018, 34(4): 779-783. doi: 10.3969/j.issn.1001-5256.2018.04.017
    [12]Sun Wei, Ding XiaoYan, Chen JingLong, Li WenDong, Guo XiaoDi, Shen YanJun, Sun ShaSha, Teng Ying, Liu XiaoMin, Wei JianYing. Clinical effect and safety of radiofrequency ablation combined with systemic chemotherapy in treatment of unresectable or postoperative recurrent intrahepatic cholangiocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1717-1722. doi: 10.3969/j.issn.1001-5256.2018.08.025
    [13]Society for Minimally Invasive Surgery, Chinese Research Hospital Association. Technical guidelines for simultaneous laparoscopic and robotic resection of colorectal cancer with liver metastasis ( Revised in 2017)[J]. Journal of Clinical Hepatology, 2018, 34(3): 494-497. doi: 10.3969/j.issn.1001-5256.2018.03.007
    [14]An DongJun, An Lin, Zhang Cheng, Zhao WeiAn, Han Li. Efficacy of laparoscopic microwave ablation in treatment of malignant liver tumors[J]. Journal of Clinical Hepatology, 2017, 33(11): 2158-2161. doi: 10.3969/j.issn.1001-5256.2017.11.021
    [15]Song Li, Zou YingHua. Prevention and treatment of complications after radiofrequency ablation for hepatic tumors in high-risk locations[J]. Journal of Clinical Hepatology, 2017, 33(4): 647-650. doi: 10.3969/j.issn.1001-5256.2017.04.009
    [16]Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
    [17]Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
    [18]Jian QianHong, Zheng FangRong, Yan Xiong. Current status of research on transcatheter arterial chemoembolization in treatment of colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1216-1219. doi: 10.3969/j.issn.1001-5256.2016.06.047
    [19]Wang Xin, Zhang Hui, He XiaoJun, Li XinHui, Liu Yang, Zhang HongYi. Clinical effect of precise sequential interventional therapy in patients with unresectable hepatic metastasis after surgery for colorectal cancer[J]. Journal of Clinical Hepatology, 2016, 32(3): 518-521. doi: 10.3969/j.issn.1001-5256.2016.03.025
    [20]Zhang ZhiQuan. Analysis of prognostic factors for patients treated by radical resection of liver metastases from colorectal cancer[J]. Journal of Clinical Hepatology, 2015, 31(9): 1455-1457. doi: 10.3969/j.issn.1001-5256.2015.09.022
  • Cited by

    Periodical cited type(11)

    1. 顾智文. 射频消融术联合奥沙利铂加卡培他滨方案用于结直肠癌术后肝转移患者的临床价值. 大医生. 2024(01): 25-28 .
    2. 刘炫鳞,买佳琪,马文兵. 脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响. 临床医学研究与实践. 2023(25): 29-32 .
    3. 林守英,周庄,刘丽雅. 薏苡附子败酱散联合XELOX方案对结直肠癌患者免疫功能、肠道菌群的影响. 实用中西医结合临床. 2023(21): 37-40 .
    4. 张洋,杨帆,王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响. 癌症进展. 2022(07): 727-730 .
    5. 苏华冠,谢礼福,刘奕武,赖光芒. 腹腔镜下结直肠癌切除术联合肝转移瘤射频消融术治疗结直肠癌肝转移. 中国肝脏病杂志(电子版). 2021(02): 13-18 .
    6. 王强. 经皮肝射频消融术联合经导管肝动脉灌注化疗治疗晚期结直肠癌多发肝转移瘤患者的效果. 中国民康医学. 2021(23): 19-22 .
    7. 刘信,刘放,刘也夫,谢峰,张睿. 术中开腹彩超引导下射频与经皮CT引导射频治疗结直肠癌肝转移疗效比较研究. 临床军医杂志. 2020(02): 167-169 .
    8. 高岩,蓝宇,贾纯增. 内镜黏膜下剥离术治疗早期结直肠癌及癌前病变临床效果观察. 临床军医杂志. 2020(06): 668-671+675 .
    9. 吕厚宽,庄文辉,刘晓晖,郭泽才,刘琪. 卡培他滨联合奥沙利铂治疗直肠癌的临床疗效研究. 长春中医药大学学报. 2020(04): 741-744 .
    10. 李江,候宇,蔡晓蓓,徐承雷,易根发. 基于限制性肝段切除手术的局部治疗模式改善结直肠癌术后肝脏寡转移的预后分析. 临床肝胆病杂志. 2020(08): 1763-1767 . 本站查看
    11. 彭文杰. AFP、CCL2和HP在结直肠癌肝转移诊断中的临床应用研究. 国际生物医学工程杂志. 2019(05): 414-418 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1684) PDF downloads(296) Cited by(12)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return